Prulifloxacin

Generic Name
Prulifloxacin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C21H20FN3O6S
CAS Number
123447-62-1
Unique Ingredient Identifier
J42298IESW
Background

Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.

Indication

用于治疗对普卢利沙星敏感的葡萄球菌、淋球菌、肺炎球菌、肠球菌、莫拉克斯氏菌、大肠杆菌、志贺杆菌、沙门氏菌(伤寒菌、副伤寒菌除外)、柠檬酸细菌、肺炎克雷伯杆菌、沙雷氏菌属、变形杆菌、霍乱弧菌、绿脓杆菌、消化链球菌引起的下列感染:

⑴浅表性皮肤感染症(急性浅表性毛囊炎、传染性脓痂疹)、深层皮肤感染症(蜂窝织炎、丹毒、疖、疖肿症、痈、化脓性甲周炎)、慢性脓皮症(感染性皮脂腺囊肿、化脓等)。

⑵肛门周围脓肿、外伤和烫伤以及手术创伤等浅表性继发性感染。

⑶急性上呼吸道感染(咽喉炎、扁桃体炎、急性支气管炎等)、慢性呼吸系统疾病的继发性感染(慢性支气管炎、弥漫性细支气管炎、支气管扩张、肺气肿、肺纤维病、支气管哮喘等)和肺炎。

⑷膀胱炎、肾盂肾炎、前列腺炎。

⑸胆囊炎、胆管炎。
...

Associated Conditions
Acute Exacerbation of Chronic Obstructive Pulmonary Disease caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Complicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated Acute Cystitis caused by susceptible bacteria
Associated Therapies
-

Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)

Phase 2
Conditions
Interventions
First Posted Date
2010-11-01
Last Posted Date
2010-11-01
Lead Sponsor
University Of Perugia
Target Recruit Count
96
Registration Number
NCT01231737

Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-03-16
Last Posted Date
2010-09-27
Lead Sponsor
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
268
Registration Number
NCT00448422
Locations
🇮🇳

Goa Medical College, Bambolim, Goa, India

Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea

First Posted Date
2006-10-26
Last Posted Date
2015-05-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
282
Registration Number
NCT00392574
Locations
🇺🇸

INC Research, New Hope, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath